- Home
- RVPHW vs DKL Comparison
RVPHW vs DKL Comparison
Compare RVPHW & DKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPHW
- DKL
- Stock Information
- Founded
- RVPHW N/A
- DKL 2012
- Country
- RVPHW United States
- DKL United States
- Employees
- RVPHW 15
- DKL N/A
- Industry
- RVPHW Biotechnology: Pharmaceutical Preparations
- DKL Natural Gas Distribution
- Sector
- RVPHW Health Care
- DKL Energy
- Exchange
- RVPHW Nasdaq
- DKL Nasdaq
- Market Cap
- RVPHW N/A
- DKL N/A
- IPO Year
- RVPHW 2018
- DKL N/A
- Fundamental
- Price
- RVPHW $0.19
- DKL $38.90
- Analyst Decision
- RVPHW
- DKL Buy
- Analyst Count
- RVPHW 0
- DKL 4
- Target Price
- RVPHW N/A
- DKL $43.00
- AVG Volume (30 Days)
- RVPHW N/A
- DKL 201.9K
- Earning Date
- RVPHW N/A
- DKL 11-06-2024
- Dividend Yield
- RVPHW N/A
- DKL 11.29%
- EPS Growth
- RVPHW N/A
- DKL N/A
- EPS
- RVPHW N/A
- DKL 2.83
- Revenue
- RVPHW N/A
- DKL $984,922,000.00
- Revenue This Year
- RVPHW N/A
- DKL $0.55
- Revenue Next Year
- RVPHW N/A
- DKL $5.17
- P/E Ratio
- RVPHW N/A
- DKL $13.76
- Revenue Growth
- RVPHW N/A
- DKL N/A
- 52 Week Low
- RVPHW N/A
- DKL $37.02
- 52 Week High
- RVPHW N/A
- DKL $53.80
- Technical
- Relative Strength Index (RSI)
- RVPHW N/A
- DKL 45.72
- Support Level
- RVPHW N/A
- DKL $37.75
- Resistance Level
- RVPHW N/A
- DKL $39.06
- Average True Range (ATR)
- RVPHW 0.00
- DKL 0.71
- MACD
- RVPHW 0.00
- DKL 0.11
- Stochastic Oscillator
- RVPHW 0.00
- DKL 47.72
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.